|
|
||||||||
|

FIGURE 5. (A) Specific activity (%ID/g*) ± SE (n = 5) of 64Cu-FC-334 in liver (
), kidney (
), EMT-6 tumor (
), blood (
), and muscle (
) at various times after intravenous administration to EMT-6 tumor-bearing SCID mice. (B) Specific activity (%ID/g*) ± SE (n = 5) of 99mTc-HL-91 in liver (
), kidney (
), EMT-6 tumor (
), blood (
), and muscle (
) at various times after intravenous administration to tumor-bearing SCID mice.
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |